These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

111 related articles for article (PubMed ID: 23513892)

  • 1. [Molecular target therapy for myelodysplastic syndrome].
    Morita Y; Tanaka H; Matsumura I
    Nihon Rinsho; 2012 Nov; 70 Suppl 8():508-12. PubMed ID: 23513892
    [No Abstract]   [Full Text] [Related]  

  • 2. Improving the outlook for myelodysplastic syndrome.
    Brower V
    J Natl Cancer Inst; 2012 Aug; 104(16):1204-6. PubMed ID: 22899627
    [No Abstract]   [Full Text] [Related]  

  • 3. Myelodysplastic syndromes (MDS).
    Klimek V
    Best Pract Res Clin Haematol; 2015 Mar; 28(1):1-2. PubMed ID: 25659724
    [No Abstract]   [Full Text] [Related]  

  • 4. New therapeutic approaches in myelodysplastic syndromes: Hypomethylating agents and lenalidomide.
    Loiseau C; Ali A; Itzykson R
    Exp Hematol; 2015 Aug; 43(8):661-72. PubMed ID: 26123365
    [TBL] [Abstract][Full Text] [Related]  

  • 5. New agents in the treatment of MDS.
    List AF
    Clin Adv Hematol Oncol; 2005 Nov; 3(11):832-4. PubMed ID: 16491623
    [No Abstract]   [Full Text] [Related]  

  • 6. [Epigenetic therapy in myelodysplastic syndromes].
    Maki K; Mitani K
    Rinsho Ketsueki; 2011 Jul; 52(7):438-46. PubMed ID: 21821974
    [No Abstract]   [Full Text] [Related]  

  • 7. The role of hypomethylating agents in myelodysplastic syndrome: changing the management paradigm.
    Merkel DG; Nagler A
    Expert Rev Hematol; 2013 Dec; 6(6):665-76. PubMed ID: 24191866
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Atypical presentations of Sweet's syndrome in patients with MDS/AML receiving combinations of hypomethylating agents with histone deacetylase inhibitors.
    Alencar C; Abramowtiz M; Parekh S; Braunshweig I; Jacobson M; Silverman L; Verma A
    Am J Hematol; 2009 Oct; 84(10):688-9. PubMed ID: 19722261
    [No Abstract]   [Full Text] [Related]  

  • 9. Current status of epigenetic treatment in myelodysplastic syndromes.
    Kuendgen A; Lübbert M
    Ann Hematol; 2008 Aug; 87(8):601-11. PubMed ID: 18392623
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Pathogenesis of and therapeutic progress for myelodysplastic syndromes].
    Miyazawa K
    Rinsho Ketsueki; 2008 Oct; 49(10):1358-67. PubMed ID: 18833920
    [No Abstract]   [Full Text] [Related]  

  • 11. Epigenetic therapies move into new territory, but how exactly do they work?
    Tuma RS
    J Natl Cancer Inst; 2009 Oct; 101(19):1300-1. PubMed ID: 19755677
    [No Abstract]   [Full Text] [Related]  

  • 12. Epigenetic therapy with decitabine for myelodysplasia and leukemia.
    Wijermans P; Lübert M
    Future Oncol; 2005 Oct; 1(5):585-91. PubMed ID: 16556035
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Therapeutic epigenetics: an emerging clinical approach to hematologic malignancies.
    Clin Adv Hematol Oncol; 2005 Mar; 3(3 Suppl 1):1-10; quiz 11-2. PubMed ID: 21438190
    [No Abstract]   [Full Text] [Related]  

  • 14. Optimizing hypomethylating agents in myelodysplastic syndromes.
    Itzykson R; Fenaux P
    Curr Opin Hematol; 2012 Mar; 19(2):65-70. PubMed ID: 22248878
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Evaluating new treatment options for MDS.
    Garcia-Manero G; Yang AS; Jagasia M
    Clin Adv Hematol Oncol; 2007 Nov; 5(11):1-9; quiz 10-2. PubMed ID: 18185491
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Novel therapeutics for myelodysplastic syndromes].
    Tohyama K
    Rinsho Ketsueki; 2011 Oct; 52(10):1535-43. PubMed ID: 21971230
    [No Abstract]   [Full Text] [Related]  

  • 17. Myelodysplastic syndromes--many new drugs, little therapeutic progress.
    Tefferi A
    Mayo Clin Proc; 2010 Nov; 85(11):1042-5. PubMed ID: 20861462
    [No Abstract]   [Full Text] [Related]  

  • 18. [The clinical research of treatment by decitabine moderate or high-risk myelodysplastic syndrome patients].
    Shao XR; Liang H; Guan XJ
    Zhonghua Xue Ye Xue Za Zhi; 2011 Nov; 32(11):789-91. PubMed ID: 22339920
    [No Abstract]   [Full Text] [Related]  

  • 19. Drug therapy for myelodysplastic syndrome: building evidence for action.
    Tefferi A; Letendre L
    Cancer; 2006 Apr; 106(8):1650-2. PubMed ID: 16532501
    [No Abstract]   [Full Text] [Related]  

  • 20. Azacitine (vidaza) for myelodysplastic syndrome.
    Med Lett Drugs Ther; 2005 Jan; 47(1201):11. PubMed ID: 15678015
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.